# OnCo record nct06757634 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06757634/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06757634", "NCT06757634" ;
  schema:name "Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)"@en ;
  schema:alternateName "VIKTORIA-2"@en ;
  schema:description "A phase 3 trial of Fulvestrant, Gedatolisib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Celcuity Inc, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06757634/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06757634> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-07-24" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/> ;
  onco:companies <https://onco.cc/companies/celcuity/> .